STAT3 and neoplasm: Consistent with this scenario are recent observations that breast cancer cells expressing mitochondria-targeted (MLS) STAT3 with a S727A mutation exhibit slower tumor growth, decreased complex I activity, and increased ROS accumulation under hypoxia compared with cells expressing MLS–STAT3 (48).